Cellectar Biosciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

FAIR VALUE (Tables)

FAIR VALUE (Tables)

6 Months Ended

Jun. 30, 2015

Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]

The following tables set forth the Company’s financial instruments carried at fair value using the lowest level of input applicable to each financial instrument as of June 30, 2015 and December 31, 2014:

	June 30, 2015
	Level 1		Level 2		Level 3		Fair Value

Liabilities:
July 2010 Warrants	$	—	$	100	$	—	$	100
February 2013 Public Offering Warrants		—		—		935,000		935,000
August 2014 Warrants		—		3,949,440		—		3,949,440
Total	$	—	$	3,949,540	$	935,000	$	4,884,540

	December 31, 2014
	Level 1		Level 2		Level 3		Fair Value

Liabilities:
July 2010 Warrants	$	—	$	999	$	—	$	999
February 2013 Public Offering Warrants		—		—		1,127,500		1,127,500
August 2014 Warrants		—		4,048,416		—		4,048,416
Total	$	—	$	4,049,415	$	1,127,500	$	5,176,915

Schedule Of Changes In Fair Value Warrants Classified Level Three [Table Text Block]

The following table summarizes the changes in the fair market value of the Company’s warrants which are classified within the Level 3 fair value hierarchy.

			Twelve Months
	Six Months Ended		Ended
	June 30,		December 31,
	2015		2014
Beginning balance – Fair value	$	1,127,500	$	3,355,000
Gain on derivatives resulting from change in fair value		(192,500)		(2,227,500)
Ending balance – Fair value	$	935,000	$	1,127,500